Leland Gershell Net Worth

The estimated Net Worth of Leland Gershell is at least $315 dollars as of 16 March 2016. Leland Gershell owns over 2,100 units of Tonix Pharmaceuticals Corp stock worth over $315 and over the last 12 years Leland sold TNXP stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Leland Gershell TNXP stock SEC Form 4 insiders trading

Leland has made over 8 trades of the Tonix Pharmaceuticals Corp stock since 2013, according to the Form 4 filled with the SEC. Most recently Leland bought 2,100 units of TNXP stock worth $5,040 on 16 March 2016.

The largest trade Leland's ever made was buying 5,000 units of Tonix Pharmaceuticals Corp stock on 9 February 2015 worth over $29,250. On average, Leland trades about 633 units every 57 days since 2013. As of 16 March 2016 Leland still owns at least 2,100 units of Tonix Pharmaceuticals Corp stock.

You can see the complete history of Leland Gershell stock trades at the bottom of the page.

What's Leland Gershell's mailing address?

Leland's mailing address filed with the SEC is C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., STE 306, NEW YORK, NY, 10022.

Insiders trading at Tonix Pharmaceuticals Corp

Over the last 12 years, insiders at Tonix Pharmaceuticals Corp have traded over $155,884 worth of Tonix Pharmaceuticals Corp stock and bought 1,820,071 units worth $3,399,062 . The most active insiders traders include Ernest Mario, Seth Lederman, and Bruce Daugherty. On average, Tonix Pharmaceuticals Corp executives and independent directors trade stock every 32 days with the average trade being worth of $2,734. The most recent stock trade was executed by Seth Lederman on 29 June 2022, trading 20,000 units of TNXP stock currently worth $34,200.

What does Tonix Pharmaceuticals Corp do?

tonix is developing innovative pharmaceutical products to address major public health challenges. in addition to tonmya for ptsd, tonix is developing tnx-601 (tianeptine oxalate), a clinical candidate at pre-ind (investigational new drug) application stage, designed as a daytime treatment for ptsd and tnx-801, a live synthetic version of horsepox virus, at the pre-ind application stage, to be developed as a potential smallpox-preventing vaccine. further information about tonix can be found at www.tonixpharma.com.

Complete history of Leland Gershell stock trades at Capricor Therapeutics Inc and Tonix Pharmaceuticals Corp

Tonix Pharmaceuticals Corp executives and stock owners

Tonix Pharmaceuticals Corp executives and other stock owners filed with the SEC include:

• Seth Lederman,
  Chairman of the Board, President, Chief Executive Officer
• Dr. Seth Lederman M.D.,
  Co-Founder, Pres, CEO & Chairman
• Dr. Seth Lederman,
  Co-Founder, Pres, CEO & Chairman
• Dr. Gregory M. Sullivan M.D.,
  Chief Medical Officer & Sec.
• Gregory Sullivan,
  Secretary, Chief Medical Officer
• Bradley Saenger CPA, CPA,
  CFO & Treasurer
• Bradley Saenger,
  Chief Financial Officer, Treasurer
• Richard Bagger,
  Director
• Herbert Harris,
  Executive Vice President - Translational Medicine
• David Grange,
  Independent Director
• Margaret Bell,
  Independent Director
• James Treco,
  Lead Independent Director
• Adeoye Olukotun,
  Independent Director
• Daniel Goodman,
  Independent Director
• Jessica Morris,
  Chief Operating Officer
• Dr. Sina Bavari Ph.D.,
  Exec. VP of Infectious Disease R&D
• Dr. Anthony Macaluso Ph.D.,
  Exec. VP of Strategic Devel.
• Dr. Darryl Rideout Ph.D.,
  Exec. VP of Experimental Chemistry
• Siobhan Fogarty B.Sc., M.Sc.,
  Exec. VP of Product Devel.
• Dr. Bruce L. Daugherty M.B.A., Ph.D.,
  Exec. VP of Research
• Dr. Herbert W. Harris M.D., Ph.D.,
  Exec. VP of Translational Medicine
• Dr. R. Michael Gendreau,
  Consultant
• Dr. Daniel J. Clauw M.D.,
  Consultant
• Dr. Ronald R. Notvest,
  Exec. VP of Commercial Planning and Devel.
• Jessica Edgar Morris,
  Chief Operating Officer
• Charles E Iv Mather,
  Director
• Ernest Mario,
  Director
• John B Rhodes,
  Director
• Samuel R Saks,
  Director
• Patrick P Grace,
  Director
• Bruce Daugherty,
  See Remarks
• Stuart Davidson,
  Director
• Donald J Kellerman,
  See Remarks
• Leland Gershell,
  CFO and Treasurer
• Carolyn E. Taylor,
  Director
• Richard Newcomb Stillwell,
  Director